Actively Recruiting
Biobank - Investigating the Gut Microbiota, Genetics, Epigenetics and Metabolites
Led by Chinese University of Hong Kong · Updated on 2023-02-08
6000
Participants Needed
1
Research Sites
1061 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Inflammatory bowel disease (IBD) affects 1 in 500 to 1,000 people in the West. Previously a disease predominantly of the West, there is now a marked increase in the incidence of ulcerative colitis (UC) and Crohn's disease (CD) in Asia, with an estimated prevalence of 1 in 3,000 and 1 in 10,000 respectively\[1\]. The rapid increase of IBD in Asian raising concern of investigators. Therefore setting up a large scale biobank with comprehensive clinical data is require.
CONDITIONS
Official Title
Biobank - Investigating the Gut Microbiota, Genetics, Epigenetics and Metabolites
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient 18 years or older with a diagnosis of Crohn's disease or ulcerative colitis
- Informed Consent obtained
You will not qualify if you...
- Known current infection with an enteric pathogen
- Previously been diagnosed with IBD (Control)
- Have a first or second degree relative with IBD (Control)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
S
Siew Chien Ng, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here